slide-1
slide-3
slide-2

WELCOME TO INNODIA

Translational approaches to disease modifying therapy of type 1 diabetes: an innovative approach towards understanding and arresting type 1 diabetes

:: 17. October 2017

EDITORIAL OF THE PATIENT ADVISORY COMMITTEE

The members of the PAC have attended the INNODIA Year 2 meeting in Cambridge in September 2017...

read more

:: 17. October 2017

Annual Meeting Cambridge

Almost 2 years after the official start of its 7-year project, INNODIA participants came together for their second annual meeting in Cambridge...

read more






About innodia

INNODIA is an international consortium under the Innovative Medicines Initiative (IMI). 26 academic institutions and clinics, 4 industrial partners (EFPIA), 2 patient organizations and one SME have joined forces to significantly improve the understanding of type 1 Diabetes and to pave the way to novel therapeutic options to prevent and cure this disease.

group

33 partner

map
corner
x
For more information select one of the following partners

ACADEMIC paRtners

  • KU Leuven
  • ULB
  • MUG
  • UCPH
  • HH RH
  • INSERM
  • UH
  • UOULU
  • UTU
  • HKA
  • HMGU
  • TUD
  • UULM
  • UNISI
  • UD‘A
  • UPI
  • CHL
  • UiO
  • SUM
  • UL
  • UNIL
  • RUMC
  • LUMC
  • UCAM
  • KCL
  • MRC

EFPIA

  • Sanofi
  • Novo Nordisk
  • Eli Lilly
  • GSK

SME

  • Univercell-Biosolutions

Foundations

  • JDRF
  • THCT
imi eu efpia jdrf helmsley